Session » Health Services Research – ACR/ARP Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1036

A Pilot Trial of Integrating Patient-Reported Outcome Measurement Information System (PROMIS®) into Rheumatology Care

10:30AM-12:30PM: Abstract Number: 1043

A Prospective Study on Early Diagnosis of Inflammatory Rheumatic Diseases Using an Enhanced Online Questionnaire System (RhePort 1.3)

10:30AM-12:30PM: Abstract Number: 1041

A Theory of Change for Patient-Initiated Follow-Up Care in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1044

Analysis of Rheumatic Patients’ Self – Reported Symptoms in Free Written Text Using Natural Language Processing

10:30AM-12:30PM: Abstract Number: 1056

Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1057

Barriers and Facilitators of Access to Physical Therapy: A Scoping Review

10:30AM-12:30PM: Abstract Number: 1052

Challenges and Opportunities in Post-Pandemic Remote Therapeutic Monitoring for Musculoskeletal Disease

10:30AM-12:30PM: Abstract Number: 1040

Clinic Personnel Perceptions Were Favorable for the Implementation of a Patient Decision-Aid for a Diverse Systemic Lupus Erythematosus Population: A Study in 15 U.S. Rheumatology Clinics

10:30AM-12:30PM: Abstract Number: 1034

Elucidating the Program Theory of a Successful Interdisciplinary Team-Based Model of Rheumatology Care: An Exploratory Case Study

10:30AM-12:30PM: Abstract Number: 1051

Healthcare Costs and Resource Utilization Associated with Long-term Medium-to-high Dose Oral Corticosteroid Use in Patients with Dermatomyositis or Polymyositis

10:30AM-12:30PM: Abstract Number: 1042

Identifying Patient Priorities for Patient-Reported Outcome Measures in Rheumatoid Arthritis: A Modified Delphi Consensus Study

10:30AM-12:30PM: Abstract Number: 1038

IMPACT (Impact of eMbedded Pharmacists in an Academic Center sTudy)

10:30AM-12:30PM: Abstract Number: 1035

Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors

10:30AM-12:30PM: Abstract Number: 1055

Impact of Provider Billing vs. Pharmacy Dispensation for Romosozumab Treatment Discontinuation Among U.S. Postmenopausal Women with Osteoporosis

10:30AM-12:30PM: Abstract Number: 1045

Impact of Stable Rheumatologic Therapy on Outcomes of Depression in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1047

Impact of Treatment Switching on Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1053

Pilot Intervention to Improve Medication Adherence Among Patients with Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 1037

Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review

10:30AM-12:30PM: Abstract Number: 1048

Self-Perception of Oral Health and Habits in Patients with Sjögren’s Syndrome, Rheumatoid Arthritis, and Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1046

Shifting Paradigms in Drug Spending: A Study of Medicare Part D versus Emerging Pharmacy Models in Rheumatology

10:30AM-12:30PM: Abstract Number: 1050

The Cost-effectiveness of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) for Patients with Knee Osteoarthritis and Obesity

10:30AM-12:30PM: Abstract Number: 1039

Through the LuCIN Lens: Defining Barriers and Forging Solutions for Lupus Clinical Trials in North America

10:30AM-12:30PM: Abstract Number: 1054

Utilization of Rehabilitation Services in Patients with Common Rheumatic Conditions: A Systematic Review

10:30AM-12:30PM: Abstract Number: 1049

Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology

« View all sessions from this meeting